Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Molecular targeting therapy for pancreatic cancer: current knowledge and perspectives from bench to bedside.

Literature DB >> 19107333

Molecular targeting therapy for pancreatic cancer: current knowledge and perspectives from bench to bedside.

Abstract

Current medical interventions for pancreatic cancer are insufficient. Recent molecular investigations have elucidated complex genetic mechanisms of cancer that especially involve multiple signal transduction pathways; this enables us to develop molecular medicines targeting specific genetic molecules in the pathways. These molecular medicines seem to promise clues for curing cancers, including pancreatic cancer. This review describes current knowledge and perspectives regarding the development of molecular medicines for pancreatic cancer by focusing on growth factor receptor systems and three major signal transduction pathways: the RAS-MAPK, PI3K-AKT-mTOR, and hedgehog pathways.

Entities: Disease

Mesh：

Substances：

Year: 2008 PMID： 19107333 DOI： 10.1007/s00535-008-2226-1

Source DB: PubMed Journal: J Gastroenterol ISSN： 0944-1174 Impact factor: 7.527

44 in total

1. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer.

Authors: Lillian L Siu; Ahmad Awada; Chris H Takimoto; Martine Piccart; Brian Schwartz; Tom Giannaris; Chetan Lathia; Oana Petrenciuc; Malcolm J Moore
Journal: Clin Cancer Res Date: 2006-01-01 Impact factor: 12.531

2. In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer.

Authors: Daisuke Ito; Koji Fujimoto; Tomohiko Mori; Kazuhiro Kami; Masayuki Koizumi; Eiji Toyoda; Yoshiya Kawaguchi; Ryuichiro Doi
Journal: Int J Cancer Date: 2006-05-01 Impact factor: 7.396

3. Inhibition of the phosphatidylinositol 3'-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo.

Authors: Victor M Bondar; Bridget Sweeney-Gotsch; Michael Andreeff; Gordon B Mills; David J McConkey
Journal: Mol Cancer Ther Date: 2002-10 Impact factor: 6.261

4. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells.

Authors: M S Tsao; S Chow; D W Hedley
Journal: Cancer Res Date: 2000-10-01 Impact factor: 12.701

5. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer.

Authors: John Rinehart; Alex A Adjei; Patricia M Lorusso; David Waterhouse; J Randolph Hecht; Ronald B Natale; Oday Hamid; Mary Varterasian; Peggy Asbury; Eric P Kaldjian; Stephen Gulyas; David Y Mitchell; Roman Herrera; Judith S Sebolt-Leopold; Mark B Meyer
Journal: J Clin Oncol Date: 2004-10-13 Impact factor: 44.544

6. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer.

Authors: E Van Cutsem; H van de Velde; P Karasek; H Oettle; W L Vervenne; A Szawlowski; P Schoffski; S Post; C Verslype; H Neumann; H Safran; Y Humblet; J Perez Ruixo; Y Ma; D Von Hoff
Journal: J Clin Oncol Date: 2004-04-15 Impact factor: 44.544

7. Survival of cancer cells is maintained by EGFR independent of its kinase activity.

Authors: Zhang Weihua; Rachel Tsan; Wei-Chien Huang; Qiuyu Wu; Chao-Hua Chiu; Isaiah J Fidler; Mien-Chie Hung
Journal: Cancer Cell Date: 2008-05 Impact factor: 31.743

8. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer.

Authors: Eric Raymond; Jérôme Alexandre; Sandrine Faivre; Karina Vera; Eric Materman; Joseph Boni; Cathie Leister; Joan Korth-Bradley; Axel Hanauske; Jean-Pierre Armand
Journal: J Clin Oncol Date: 2004-05-10 Impact factor: 44.544

9. Mutations of the BRAF gene in human cancer.

Authors: Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal: Nature Date: 2002-06-09 Impact factor: 49.962

10. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.

Authors: Scott M Wilhelm; Christopher Carter; Liya Tang; Dean Wilkie; Angela McNabola; Hong Rong; Charles Chen; Xiaomei Zhang; Patrick Vincent; Mark McHugh; Yichen Cao; Jaleel Shujath; Susan Gawlak; Deepa Eveleigh; Bruce Rowley; Li Liu; Lila Adnane; Mark Lynch; Daniel Auclair; Ian Taylor; Rich Gedrich; Andrei Voznesensky; Bernd Riedl; Leonard E Post; Gideon Bollag; Pamela A Trail
Journal: Cancer Res Date: 2004-10-01 Impact factor: 13.312

20 in total

1. dmGWAS: dense module searching for genome-wide association studies in protein-protein interaction networks.

Authors: Peilin Jia; Siyuan Zheng; Jirong Long; Wei Zheng; Zhongming Zhao
Journal: Bioinformatics Date: 2010-11-02 Impact factor: 6.937

2. Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis.

Authors: Nagathihalli S Nagaraj; J Joshua Smith; Frank Revetta; M Kay Washington; Nipun B Merchant
Journal: Mol Cancer Ther Date: 2010-08-03 Impact factor: 6.261

3. Glycogen synthase kinase 3β inhibition sensitizes pancreatic cancer cells to gemcitabine.

Authors: Takeo Shimasaki; Yasuhito Ishigaki; Yuka Nakamura; Takanobu Takata; Naoki Nakaya; Hideo Nakajima; Itaru Sato; Xia Zhao; Ayako Kitano; Kazuyuki Kawakami; Takuji Tanaka; Tsutomu Takegami; Naohisa Tomosugi; Toshinari Minamoto; Yoshiharu Motoo
Journal: J Gastroenterol Date: 2011-11-01 Impact factor: 7.527

Review 4. Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer.

Authors: Pavan P Adiseshaiah; Rachael M Crist; Sara S Hook; Scott E McNeil
Journal: Nat Rev Clin Oncol Date: 2016-08-17 Impact factor: 66.675

5. Plasma Shh levels reduced in pancreatic cancer patients.

Authors: Mohamad El-Zaatari; Stephanie Daignault; Art Tessier; Gail Kelsey; Lisa A Travnikar; Esperanza F Cantu; Jamie Lee; Caitlyn M Plonka; Diane M Simeone; Michelle A Anderson; Juanita L Merchant
Journal: Pancreas Date: 2012-10 Impact factor: 3.327